scholarly journals Treatment of Degenerative Disc Disease With Allogeneic Mesenchymal Stem Cells: Long-term Follow-up Results

2021 ◽  
Vol 105 (2) ◽  
pp. e25-e27
Author(s):  
David C. Noriega ◽  
Francisco Ardura ◽  
Rubén Hernández-Ramajo ◽  
Miguel Ángel Martín-Ferrero ◽  
Israel Sánchez-Lite ◽  
...  
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ajay Matta ◽  
Muhammad Zia Karim ◽  
Hoda Gerami ◽  
Bettina Benigno ◽  
W. Mark Erwin

AbstractCellular replacement therapy using mesenchymal stem cells (MSCs) and/or the delivery of growth factors are at the forefront of minimally invasive biological treatment options for Degenerative Disc Disease (DDD). In this study, we compared the therapeutic potential of a novel drug candidate, NTG-101 to MSCs, including rat cartilage derived stem cells (rCDSCs), bone marrow stem cells (rBMSCs) and human Umbilical Cord Derived Mesenchymal Stem Cells (hUCMSCs) for the treatment of DDD. We induced DDD using a validated image-guided needle puncture injury in rat-tail IVDs. Ten weeks post-injury, animals were randomized and injected with MSCs, NTG-101 or vehicle. At the end of the study, histological analysis of the IVD-Nucleus Pulposus (NPs) injected with NTG-101 or rCDSCs showed a healthy or mild degenerative phenotype in comparison to vehicle controls. Immunohistochemical analysis revealed strong expression of aggrecan, collagen 2, brachyury and Oct4 in IVD-NPs injected with NTG-101. Our results also demonstrated suppression of inflammation induced p38 and NFκB resulting in inhibition of catabolic genes, but activation of Smad-2/3, Erk-1/2 and Akt-dependent signaling inducing anabolic genes in IVD-NP on treatment with NTG-101. In conclusion, a single injection of NTG-101 into the degenerative disc demonstrated superior benefits compared to stem cell transplantation.


2018 ◽  
Vol 13 (3) ◽  
pp. 295-307 ◽  
Author(s):  
Yang Song ◽  
Hui Du ◽  
Chengxiang Dai ◽  
Li Zhang ◽  
Suke Li ◽  
...  

2019 ◽  
Vol 10 (1) ◽  
pp. 30-38
Author(s):  
Haider Kareem ◽  
Christian Ulbricht

Study Design: Prospective cohort study. Objective: To evaluate the long-term effectiveness of a posterior dynamic spine stabilization (PDS) System called PercuDyn system as a treatment for low back pain (LBP) in patients with degenerative disc disease who have failed conservative treatment. Methods: Thirty-five patients (21 males, 14 females, mean age 36 years) with chronic LBP due to degenerative disc disease underwent percutaneous facet augmentation with the PercuDyn system. Indications for implanting the PercuDyn device were chronic LBP without sciatica, significant disc degeneration, and who failed conservative treatment. Follow-up after surgery ranged from 4 to 8 years. Patients were clinically evaluated using visual analogue scale (VAS), Oswestry Disability Index (ODI) questionnaire, and the EQ-5D3L. Results: The VAS scale and ODI scores improved at 6 months, 1 year, 2 years, and 4 to 8 years in comparison with the baseline values ( P < .001 and P < .01, respectively). Equally, data from the EQ-5D-3L questionnaire suggested improvements in all domains, including pain and discomfort, over the follow-up period. However, during follow-up, 16 patients (46%) have had unsatisfactory outcome including failure of implant to resolve symptoms (n = 8), developed symptomatic disc protrusion (n = 4), and loosening of the screws (n = 4). Conclusion: Our clinical experience highlights the rather high overall failure rate of this system. Although, some patients show significant improvement in their symptoms, we believe that patients with LBP related to degenerative disc disease are a poor indication for this PDS device.However, large scale studies, with optimised selection criteria are needed to demonstrate the exact role of this device in spinal patients.


2015 ◽  
Vol 90 (6) ◽  
pp. 747-755 ◽  
Author(s):  
Rachele Ciccocioppo ◽  
Alessandra Gallia ◽  
Adele Sgarella ◽  
Peter Kruzliak ◽  
Paolo G. Gobbi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document